RT Journal Article
SR Electronic
T1 Improved Global Response Outcome After Intradetrusor Injection of Adult Muscle-Derived Cells for the Treatment of Underactive Bladder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.16.20132779
DO 10.1101/2020.06.16.20132779
A1 Jason Gilleran
A1 Ananias C. Diokno
A1 Elijah Ward
A1 Larry Sirls
A1 Deborah Hasenau
A1 Jennifer Giordano
A1 Evelyn Shea
A1 Sarah N. Bartolone
A1 Laura E. Lamb
A1 Michael B. Chancellor
YR 2020
UL http://medrxiv.org/content/early/2020/06/19/2020.06.16.20132779.abstract
AB We report on the first regulatory approved clinical trial of a prospective open-label physician-initiated study assessing the safety and efficacy of intradetrusor injected Autologous Muscle Derived Cells (AMDC) treatment for underactive bladder (UAB).20 non-neurogenic UAB patients were treated. Approximately 50-250 mg of quadriceps femoris muscle was collected using a spirotome 8-gauge needle. The muscles biopsy samples were sent to Cook MyoSite (Pittsburgh, PA) for processing, isolation, and propagation of cells. Research patients received approximately 30 intradetrusor injections of 0.5 mL delivered to the bladder, for a total of 15 mL and 125 million AMDC, performed utilizing a flexible cystoscope under direct vision using topical local anesthesia. Follow-up assessments included adverse events and efficacy via voiding diary and urodynamic testing at 1, 3, 6 & 12-month post-injection. An optional second injection was offered at the end of the 6 months visit.20 patients received the first injection and all 20 patients requested and received a second injection. Median patient age was 65 years old (range 41-82 years). There were 16 male (80%) and 4 female (20%) patients. Etiology included 7 men (35%) with persistent urinary retention after transurethral resection of the prostate for benign prostatic hyperplasia and 13 patients (65%) with idiopathic chronic urinary retention. At the primary outcome time point of 12 months, 11/19 patients (58%) reported a global response assessment (GRA) ≥ 5, showing slight to marked improvement in their UAB symptoms, compared to 6/20 (30%) patients at 3-months post-injection. No serious procedure or treatment-related adverse events occurred. Noted improvements included: decreased post void residual urine volume, increased voiding efficiency, and decreased catheter use.Intradetrusor injected AMDC as a treatment for UAB was successfully completed in a 20-patient trial without serious adverse event and with signal of efficacy. Cellular therapy may be a promising novel treatment for catheter dependent chronic urinary retention. A multicenter controlled trial is needed to further assess the promise of regenerative medicine in the treatment of lower urinary tract dysfunction.Competing Interest StatementDr. Michael Chancellor, a urologist and researcher at William Beaumont Hospital, is one of the inventors of this cell process. Dr. Chancellor receives royalty payments for the cell process and consulting from Cook MyoSite, the company which owns the rights to the cell process and prepares the cells for re-implantation.Clinical TrialClinicalTrial.gov; NCT02463448Funding StatementThe Aikens Research Center at Beaumont Health System (Royal Oak, MI, USA). The authors would like to acknowledge the NIA, NIDDK, the Underactive Bladder Foundation (www.underactivebladder.org).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This was a physician sponsored, single center, two-year prospective, open-label, clinical trial, assessing the safety and efficacy of intradetrusor injected AMDC as a treatment for UAB in 20 research participants (ClinicalTrial.gov; NCT02463448). This study received approval from the Beaumont Investigational Review Board (IRB# 2015-134). Written consent from all participants was obtained prior to initiating any study activity.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available upon request.